Form 4: Third Rock Ventures Reports Beneficial Ownership Changes in Maze Therapeutics Following IPO

Third Rock Ventures files Form 4 detailing the conversion of preferred stock to common stock and changes in beneficial ownership following Maze Therapeutics' initial public offering.

Summary

• Third Rock Ventures IV, L.P. and related entities, along with Third Rock Ventures V, L.P. and related entities, reported changes in their beneficial ownership of Maze Therapeutics, Inc. common stock on February 3, 2025.
• The changes are primarily due to the automatic conversion of Series A Preferred Stock and Series D-1 Preferred Stock into common stock at a ratio of 1-for-0.1037 upon the closing of Maze Therapeutics' IPO.
• Third Rock Ventures IV, L.P. directly holds 6,073,958 shares of common stock after the reported transactions.
• Third Rock Ventures V, L.P. directly holds 950,800 shares of common stock after the reported transactions.
• The reporting persons disclaim beneficial ownership of the shares except to the extent of their pecuniary interest.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing, indicating a neutral sentiment. The successful IPO is a positive event, but the filing itself is simply a procedural requirement.

Positives

• The conversion of preferred stock to common stock simplifies the capital structure of Maze Therapeutics following its IPO.
• Third Rock Ventures maintains a significant ownership stake in Maze Therapeutics.

Industry Context

Form 4 filings are standard practice after an IPO, providing transparency into the ownership structure of the newly public company. Venture capital firms like Third Rock Ventures often hold significant stakes in companies they invest in, and their ownership changes are closely watched by investors.

Comparison to Industry Standards

• Similar filings are common for venture capital firms after portfolio companies go public, for example, Flagship Pioneering's filings after Moderna's IPO or Kleiner Perkins' filings after Google's IPO.
• The conversion ratio of 1-for-0.1037 is specific to the terms negotiated for Maze Therapeutics' preferred stock.

Stakeholder Impact

• The filing provides transparency to shareholders regarding the ownership structure of Maze Therapeutics.
• Employees and other stakeholders may be interested in the ownership changes as they reflect the involvement of major investors.

Key Dates

Keywords

Form 4, beneficial ownership, Maze Therapeutics, Third Rock Ventures, common stock, preferred stock, conversion, IPO